Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorcaserin for Cannabis Use Disorder
NCT03637842Phase 1Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Aug 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cannabis use disorder (CUD) comparing Lorcaserin XR with Placebo (2 arms). Primary endpoint: Number of Participants Who Achieved a Reduction in Cannabis Use Per Daily Quartiles at 13 weeks. Started Aug 2019; status: terminated.
02
Drugs
lorcaserin
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT03637842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03637842.